Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants achieving full biochemical control | Defined as fasting Growth Hormone (GH) ≤ 2.5 μg/L and Insulin-like Growth Factor-1 (IGF-1) normalization | At 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants achieving fasting GH < 1 μg/L and IGF-1 normalization | At 12 months | |
| Percentage of participants achieving fasting GH ≤2.5 μg/L and IGF-1 ≤1.3 Upper Limit of Normal (ULN) | At 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult participants who have been diagnosed with acromegaly and initiating LAN treatment
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ipsen Medical, Director | Ipsen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking Union Medical College Hospital (PUMCH) | Beijing | 100000 | China | |||
| Peking University Third Hospital (PUH3) |
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
Not provided
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
Not provided
| ID | Term |
|---|---|
| D000172 | Acromegaly |
| ID | Term |
|---|---|
| D001849 | Bone Diseases, Endocrine |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D006964 | Hyperpituitarism |
Not provided
Not provided
Not provided
Not provided
Not provided
| Mean change in fasting GH and IGF-1 concentrations. | From baseline to 3, 6, and 12 months |
| Mean change in the proportion of patients experiencing each of the symptoms (headache, excessive sweating, joint pain, fatigue, and soft tissue swelling) as evaluated by physicians. | From baseline to 6 and 12 months |
| Mean change in Quality of Life (QoL) scores | Assessed by the Acromegaly Quality of Life Questionnaire (AcroQoL). | From baseline to 6 and 12 months |
| Treatment utilisation of LAN, evaluated by the total number of injections received | From baseline to 12 months |
| Treatment utilisation of LAN, evaluated by number of participants in Extended Dosing Interval (EDI) | From baseline to 12 months |
| Incidence of all Adverse Events (AEs) | Including Serious Adverse Events (SAEs) and special situations assessed according to incidence, intensity, causality, outcome, action taken, and seriousness. | From baseline to 3, 6 and 12 months |
| Mean change in physical examination results | Including Body Mass Index (BMI) and weight | From baseline to 3, 6, and 12 months |
| Mean change in vital signs blood pressure | From baseline to 3, 6, and 12 months |
| Mean change in vital signs heart rate | From baseline to 3, 6, and 12 months |
| Mean change in Clinical laboratory assessments | Including fasting blood glucose, glycated hemoglobin A1C (HbA1c), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL, and triglycerides | From baseline to 6, and 12 months |
| Mean change in free thyroxine (FT4) and cortisol for males and females | From baseline to 6 and 12 months |
| Mean change in testosterone for males only | From baseline to 6 and 12 months |
| Mean change in follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol for females only. | From baseline to 6 and 12 months |
| Beijing |
| 100000 |
| China |
| Xiangya Hospital Central South University (XYHCSU) | Changsha | 410000 | China |
| West China Hospital，Sichuan University (WCH) | Chengdu | 610000 | China |
| The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU) | Guangzhou | 510000 | China |
| The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU) | Hangzhou | 310000 | China |
| Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School (NJDTH) | Nanjing | 210000 | China |
| The First Hospital of China Medical University (CMU1H) | Shenyang | 110000 | China |
| The Second Hospital of Hebei Medical University (HB2H) | Shijiazhuang | 050000 | China |
| Affiliated Hospital of Wenzhou Medical University (FAHWMU) | Wenzhou | 325000 | China |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology (TJH HUST) | Wuhan | 430000 | China |
| The First Affiliated Hospital of Zhengzhou University (FAHZZU) | Zhengzhou | 450000 | China |
| D010900 |
| Pituitary Diseases |
| D007027 | Hypothalamic Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D004700 | Endocrine System Diseases |